SEATTLE--(BUSINESS WIRE)--Targeted Genetics Corporation (NASDAQ:TGEN) (the “Company”) today announced that it has determined that the expense and management attention required for NASDAQ Capital Market and Securities and Exchange Commission (“SEC”) compliance outweigh the benefits for the Company and its shareholders at this time. The Company believes that its limited resources may be more productively utilized to support continued efforts to monetize certain assets, to realize value from milestone and royalty licensing relationships, and to support product development programs currently underway with commercial and academic partners.
